IBRX - Immunitybio - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IBRX is currently covered by 2 analysts with an average price target of $10.56. This is a potential upside of $7.7 (269.23%) from yesterday's end of day stock price of $2.86.

Immunitybio's activity chart (see below) currently has 22 price targets and 33 ratings on display. The stock rating distribution of IBRX is 22.22% HOLD and 77.78% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 56.36% with an average time for these price targets to be met of 202.75 days.

Highest price target for IBRX is $30, Lowest price target is $5, average price target is $17.5.

Most recent stock forecast was given by JASON KOLBERT from D. BORAL CAPITAL on 25-Jul-2025. First documented stock forecast 16-May-2017.

Best performing analysts who are covering IBRX - Immunitybio:

Kelly Shi Joseph Catanzaro Joel Beatty Jason Kolbert

Currently out of the existing stock ratings of IBRX, 4 are a HOLD (22.22%), 14 are a BUY (77.78%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$30

$27.14 (948.95%)

$30

1 days ago
(25-Jul-2025)

0/14 (0%)

$27.14 (948.95%)

Hold

$5

$2.14 (74.83%)

$4.75

2 months 6 days ago
(20-May-2025)

5/11 (45.45%)

$2.1 (72.41%)

103

Buy

$5

$2.14 (74.83%)

$8

2 years 2 months 11 days ago
(15-May-2023)

2/2 (100%)

$1.78 (55.28%)

431

Sell

$0.8

$-2.06 (-72.03%)

$1.25

6 years 1 months 25 days ago
(31-May-2019)

4/5 (80%)

$-0.23 (-22.33%)

277

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IBRX (Immunitybio) average time for price targets to be met?

On average it took 202.75 days on average for the stock forecasts to be realized with a an average price target met ratio 56.36

Which analyst has the current highest performing score on IBRX (Immunitybio) with a proven track record?

KELLY SHI

Which analyst has the current lower performing score on IBRX (Immunitybio) with a proven track record?

JASON KOLBERT

Which analyst has the most public recommendations on IBRX (Immunitybio)?

Kelly Shi works at JEFFERIES and has 4 price targets and 2 ratings on IBRX

Which analyst is the currently most bullish on IBRX (Immunitybio)?

Jason Kolbert with highest potential upside - $27.14

Which analyst is the currently most reserved on IBRX (Immunitybio)?

Joel Beatty with lowest potential downside - -$2.06

Immunitybio in the News

ImmunityBio's ANKTIVA Gains UK Approval In Bladder Cancer Treatment

(RTTNews) – ImmunityBio Inc. (IBRX) announced that the UK Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. ANKTIVA...

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA’s first marketing approval outside the U.S. ANKTIVA plus BCG offers a new option for eligible patients...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?